Farmácia/Notícias da Indústria

Estudo randomizado | Vacina da Novavax confere 89,7% de proteção contra infecção sintomática por SARS-CoV-2 e 100% de proteção contra hospitalizações ou mortes.

1 Jul, 2021 | 10:25h

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine – New England Journal of Medicine

Entrevista de áudio: Audio Interview: Another New Covid-19 Vaccine – New England Journal of Medicine

Relacionado: Opinion | The mRNA vaccines are extraordinary, but Novavax is even better

---

Vacinas contra COVID-19 reduzem a gravidade, a duração e a carga viral daqueles que se infectam mesmo após a vacinação.

1 Jul, 2021 | 10:21h

COVID-19 vaccine reduces severity, length, viral load for those who still get infected – University of Arizona Health Sciences

Estudo original: Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines – New England Journal of Medicine

 

Comentário no Twitter

The @CDCgov trial to rigorously assess mRNA vaccination suppression of covid infections as assessed with frequent NP swabs in nearly 4,000 participants
91% efficacy of blocking transmission of infection (2 doses); 40% reduction of viral load https://t.co/tI6LECbw42 pic.twitter.com/y85Vd9ih5A

— Eric Topol (@EricTopol) June 30, 2021

 

---

Estudo randomizado | Desfechos similares para o tratamento de 5 ou de 2 anos com zoledronato após quimioterapia adjuvante no câncer de mama inicial.

1 Jul, 2021 | 10:14h

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer – The ASCO Post

Estudo original: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

---

Série de casos | Miocardite após imunização com vacinas de mRNA contra COVID-19.

30 Jun, 2021 | 10:47h

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military – JAMA Cardiology

Ver também: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology

Editoriais: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines E Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working

Comentário: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD

Relacionado: CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

 

Comentário no Twitter

2 new reports of myocarditis after mRNA vaccination documenting its rare occurrence
23 males serving in the military among 2.8 million doses givenhttps://t.co/yPbYxkuSHi
4 cases in North Carolina, including a 70-year-old womanhttps://t.co/Iwj2Hx6O2U@JAMACardio pic.twitter.com/fv2JoOFAyt

— Eric Topol (@EricTopol) June 29, 2021

 

---

Exclusivo | OMS estima que sejam necessárias doses anuais de reforço das vacinas contra COVID-19 para os mais vulneráveis.

30 Jun, 2021 | 10:45h

Exclusive-WHO estimates COVID-19 boosters needed yearly for most vulnerable – Reuters

Relacionado: CDC group says there isn’t enough data yet to recommend Covid booster shots – CNBC

---

Devo tomar a segunda dose da vacina da AstraZeneca? Sim; ela quase dobra sua proteção contra a variante Delta.

30 Jun, 2021 | 10:41h

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta – The Conversation

Relacionado: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv

---

M-A | Em pacientes com insuficiência cardíaca, os inibidores de SGLT-2 reduzem a morte por causa cardiovascular e as hospitalizações.

30 Jun, 2021 | 10:39h

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis – EClinicalMedicine

---

Estudo randomizado fase 1/2 | CoronaVac é bem tolerada, segura e induz forte resposta humoral em crianças e adolescentes de 3 a 17 anos de idade.

29 Jun, 2021 | 09:54h

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Comentário convidado: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases

 

Comentário no Twitter

NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc

— The Lancet (@TheLancet) June 28, 2021

 

---

Relato de caso | Trombose com trombocitopenia após vacina de RNA mensageiro–1273.

29 Jun, 2021 | 09:53h

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Comentário: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

---

Vacinas de mRNA contra SARS-CoV-2 induzem respostas persistentes do centro germinativo humano, sugerindo uma imunidade de longa duração.

29 Jun, 2021 | 09:52h

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature

Comentários: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical

Relacionado: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.

 

Comentário no Twitter (fio – clique para saber mais)

Just published @nature
A bonus factor after covid vaccination: germinal center factories for durable, antigen-specific, B cells and plasmoblasts induced by mRNA vaccination, as determined by lymph node aspirates from vaccinees https://t.co/5eR0gDSWHq@TheBcellArtist @WUSTLmed pic.twitter.com/C5xPSrh5Gw

— Eric Topol (@EricTopol) June 28, 2021

 

---